A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

Overview of attention for article published in Blood, November 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 1 news outlet

twitter: 12 X users

Readers on

mendeley: 103 Mendeley

So far, Altmetric has seen 14 X posts from 12 X users, with an upper bound of 75,368 followers.

RT @michaelwangmd: In this study by Nancy L Bartlett from Washington School of Medicine, CD30/CD16A-bispecific ab AFM13, an innate immune c…

In this study by Nancy L Bartlett from Washington School of Medicine, CD30/CD16A-bispecific ab AFM13, an innate immune cell engager when used with pembrolizumab in R/R HL had an ORR of 88% at the highest treatment dose, with an 83% overall RR https://t.…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 10 additional X posts.